In this study, patients began treatment with chemotherapy
using cyclophosphamide and topotecan and the experimental monoclonal antibody hu14.18 K322A.
Johns Hopkins Kimmel Cancer Center scientists first
used cyclophosphamide to prevent severe graft - versus - host disease (GVHD) after bone marrow transplant involving haploidentical or «half - matched» transplants, a treatment first used in 2000 at the Cancer Center to treat leukemias and other blood cancers.
Not exact matches
In the early 2000s, Johns Hopkins scientists Leo Luznik and Ephraim Fuchs found that giving patients high doses of
cyclophosphamide — a drug derived from nitrogen mustard and
used to treat blood cancers — three days after bone marrow transplant successfully thwarts acute and chronic GVHD.
Medical centers around the world now
use the Johns Hopkins protocol of post-transplant
cyclophosphamide, and Luznik says the inexpensive drug is becoming increasingly mainstream in bone marrow transplant regimens.
The scientists began to
use post-transplant
cyclophosphamide in clinical trials of fully matched bone marrow transplants in 2004.
Cisplatin and
cyclophosphamide were the other drugs
used in this study.
The trick with subtractive immunization is to first tolerize an organism - with a non-metastatic tumor cell,
using an immune suppressant chemical like
cyclophosphamide to kill off all the immune cells that recognize the immunodominant antigens.
Chemotherapy
uses a combination of
cyclophosphamide, vincristine and prednisone (CHOP chemotherapy protocol is commonly
used).
Tell your veterinarian if your pet is
using any of the following medications: Buspirone, cisapride,
cyclophosphamide, cyclosporine, thiazide diuretics (Dyazide, Diuril), NSAIDS (Rimadyl, Novox), theophylline / aminophylline, tricyclic antidepressants (clomipramine, Clomicalm, amitriptyline), sulfonylurea ant - diabetics (glipizide, glyburide), warfarin (Coumadin).